Lindbrook Capital’s Karyopharm Therapeutics KPTI Stock Holding History

Lindbrook Capital’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-27	Closed	-$1.55K	–	2800
2023 Q1	$1.55K	Buy	+27	New	+$1.33K	﹤0.01%	2342
2022 Q4	–	Sell	-3	Closed	–	–	2922
2022 Q3	$0	Sell	3 -13	-81%	-$971	﹤0.01%	2772
2022 Q2	$1K	Buy	+16	New	+$1.47K	﹤0.01%	2282
2021 Q3	–	Sell	-38	Closed	-$6K	–	1932
2021 Q2	$6K	Buy	+38	New	+$5.51K	﹤0.01%	1245
2021 Q1	–	Sell	-213	Closed	-$50K	–	1904
2020 Q4	$50K	Buy	213 +209	+5,225%	+$48.4K	0.01%	400
2020 Q3	$1K	Sell	4 -29	-88%	-$7.09K	﹤0.01%	1585
2020 Q2	$9K	Buy	+33	New	+$9.76K	﹤0.01%	874

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Lindbrook Capital's KPTI Position: Q2 2023 in Review

Lindbrook Capital sold out of Karyopharm Therapeutics (KPTI) in Q2 2023, closing a stake of 27 shares — an estimated $1.55K sold.

Lindbrook Capital first reported a position in KPTI in Q2 2020 and held it in 7 quarters. The position peaked at $50K in Q4 2020. 137 funds tracked by Wall St. Rank hold KPTI as of Q2 2023.

Lindbrook Capital reported no remaining Karyopharm Therapeutics position as of Q2 2023 after selling out during the quarter.
Lindbrook Capital sold 27 Karyopharm Therapeutics shares in Q2 2023, an estimated $1.55K.
Lindbrook Capital first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 7 quarters.
Lindbrook Capital's Karyopharm Therapeutics position peaked at $50K in Q4 2020.
137 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2023.

Based on Lindbrook Capital's 13F filing for Q2 2023, filed 31 Jul 2023.